$COCP

Cocrystal Pharma, Inc. (COCP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 12, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed Carol L. B

Original reporting
Published Aug 18, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$COCP
Neutral
medium confidence
Mentioned
$COCP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COCPNeutralLow
01

Why it matters

The disclosure confirms a new director appointment effective immediately, with no related-party transactions requiring Item 404(a) disclosure.

02

Market read

This is a routine governance update. It may slightly influence sentiment, but it does not introduce new financial guidance, clinical, regulatory, or deal catalysts.

03

What to watch

Check for any concurrent committee assignments, compensation details, or follow-on filings (proxy/other 8-K items) that could make the appointment more material than it appears here.

Relevance 6/10Novelty 3/10Timing: filed Aug. 18, 2026, covering an Aug. 12 director appointment

Background

The company filed an SEC Form 8-K under Item 5.02 for director/officer changes and compensatory arrangements.

Company-level read

Ticker impact

$COCPNeutralMedium confidence
Context

Cocrystal Pharma appointed Carol L. Brosgart as a director effective immediately, disclosed in its Aug. 12, 2026 8-K.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely modest and short-lived.

Evidence & confidence

The filing discloses a new director appointment without related-party transactions or additional operational/financial commitments, so incremental information is limited.

Market effects

Minimal sector read-through; this is company-specific governance news.

No clear regional spillover expected.

No direct global market relevance indicated.

Counterpoint

The appointment could be a precursor to broader strategic changes, but the 8-K provides no such details, so traders may be overreacting if they extrapolate.

Key entities

  • Cocrystal Pharma, Inc.

    Nasdaq-listed company filing the 8-K for a director appointment.

  • Carol L. Brosgart

    Appointed as a director effective immediately on Aug. 12, 2026.

  • James Martin

    CFO signing the filing.

Related articles

$GEHighAI 8/10

GE Looks 15.6% Overvalued on GF Value™ as Boeing 777X Engine Upd

GE Aerospace's CFO addressed durability concerns about the GE9X engine, assuring no delay for Boeing's 777X. The company redesigned the component and began shipping updated engines. GE's stock is trading at $313.47, 15.6% above its GF Value™ of $271.20, indicating modest overvaluation. The company's GF Score™ is 76/100, with strong momentum but mixed insider and guru activity.

$JPMMedAI 8/10

JPMorgan Chase (JPM) Commits $750 Billion to Rebuilding America’s Housing Supply

JPMorgan Chase (JPM) plans to invest $750 billion by 2035 to boost U.S. housing supply, including financing 1 million affordable units and aiding 500,000 homebuyers. The bank reported record Q2 net income of $21.2 billion, supporting its expanded housing efforts. Potential benefits include increased mortgage revenue and customer relationships, but risks include credit exposure and market conditions.

$AXONMedAI 8/10

Axon Rebounded 6% Wednesday. Here’s What Could Drive the Stock Through 2026

Axon Enterprise's stock rebounded 6% to $468 on Wednesday after a 10% drop following a $1 billion convertible notes offering. The company expects 32-34% revenue growth in 2026, with strong Q4 growth anticipated. Analysts maintain bullish targets, citing Axon's faster expansion compared to competitors like Motorola Solutions. The stock has an implied upside of 56% based on a valuation model target of $706.

$CRWVHighAI 9/10

Why CoreWeave Stock Dived by More Than 5% Today

CoreWeave (CRWV) stock fell over 5% after announcing two fundraising measures: an at-the-market stock offering of up to 35 million shares and a $3 billion convertible senior notes issue. The company plans to use proceeds for financing flexibility, credit profile improvement, and general corporate purposes. CoreWeave has $43.5 billion in long-term debt and added $25 billion in new customer commitments this quarter.

$GLOHighAI 9/10

US approves $414M uranium investment in Niger, two years after troops left

The US Development Finance Corp approved a $414M debt facility for Canadian miner Global Atomic’s Dasa uranium project in Niger, aiming to secure strategic uranium supply. The project is the highest-grade uranium deposit in Africa, according to the company. The investment comes amid Niger's dispute with French miner Orano and strained US-Canada relations. Security and political risks remain due to recent mutiny attempts in Niger.

$AONHighAI 9/10

Aon announces $13.4 billion senior notes offering to support USI acquisition

Aon plc (NYSE:AON) completed a $13.4 billion senior notes offering to support its acquisition of USI Advantage Corp. The notes, issued by Aon North America and Aon Global Holdings, include multiple series with varying maturities and interest rates. Proceeds will fund the acquisition, repay USI's debt, and cover related expenses. The offering was filed with the SEC and listed on the NYSE.